Massivemarkets

INO

Inovio Pharmaceuticals, Inc.

Nasdaq · usd

$1.76+0.05 (+2.92%)
At close · 15-minute delayed
$1.84+0.08 (+4.54%)
As of 7:59:56 PM EST on Nov 20, 2026 · After hours

Inovio Pharmaceuticals, Inc. (INO) trades at $1.76 (+2.92%) as of 7:59:56 PM EST on Nov 20, 2026, +109.80% over the past month. Market cap is $329.66M, with 1.8 days to cover in short interest.

Stock performance

How Inovio Pharmaceuticals, Inc. (INO) stock has performed from one day to one year, with its 52-week range.

+8.88%
+$0.15 over 1D
$1.64$1.71$1.78$1.844:00 AM8:55 AM12:35 PM4:10 PM8:00 PM$1.84
1D
+2.92%
1W
+23.08%
1M
+109.80%
YTD
+1.15%
1Y
-2.76%
52-wk range
$0.56 – $2.72

Key statistics

Today's trading snapshot for INO: day range, open, previous close, volume and market cap.

Day range
$1.62 – $1.78
Open
$1.73
Prev close
$1.71
Volume
7.92M
Market cap
$329.66M
Shares out
110.18M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Inovio Pharmaceuticals, Inc.: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
1102.91
P/B
-9.72
P/FCF
—
ROE
209.7%
ROA
-118.3%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 20, 2026

8-K filings

Material corporate events Inovio Pharmaceuticals, Inc. has disclosed to the SEC on Form 8-K.

  • Director appointmentNov 17, 2026

    Effective November 13, 2026, the Board of Directors (the "Board") of Inovio Pharmaceuticals, Inc. (the "Company") increased the size of the Board from eight to nine directors and appointed Jeffrey Libson to fill the newly created directorship. Mr. Libson will hold office until the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal.

  • Quarterly earningsNov 10, 2026

    On November 10, 2026, Inovio Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2026.

  • Underwriting agreementNov 9, 2026

    On November 5, 2026, Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters, relating to the issuance and sale by the Company in a public offering.

  • Product or service launchNov 2, 2026

    VOCERYQ was approved in combination with CELLECTRA® 5PSP, the Company's proprietary DNA medicine delivery device. The Company expects to make VOCERYQ available to order and ship in approximately 60 days and anticipates full field deployment during the first quarter of 2027.

  • Bylaw amendmentOct 6, 2026

    On October 6, 2026, the Board of Directors (the "Board") of Inovio Pharmaceuticals, Inc. (the "Company") approved and adopted an amendment (the "Bylaws Amendment") to the Amended and Restated Bylaws of the Company, effective immediately. The Bylaws Amendment adds a new Article 12 (Exclusive Forum), which provides that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for certain specified actions... In addition, the Bylaws Amendment provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.

Dividend history and stock splits

Inovio Pharmaceuticals, Inc.'s recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-12Jan 25, 2024
  • 1-for-4Jun 6, 2014

INO short interest

How heavily INO is shorted: shares short, days to cover and average daily volume.

Days to cover
1.8
Short interest
22.1M
Avg volume
12.15M

As of · reported to FINRA twice monthly.

INO news

The latest news and headlines about Inovio Pharmaceuticals, Inc. (INO).

Frequently asked questions

What is the Inovio Pharmaceuticals, Inc. (INO) stock price today?

Inovio Pharmaceuticals, Inc. (INO) is trading at $1.76 (+2.92% on the day) as of 7:59:56 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Inovio Pharmaceuticals, Inc.?

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases.

What is the short interest in INO?

As of Oct 30, 2026, INO has 22.1M shares short and 1.8 days to cover.

What exchange is INO listed on?

Inovio Pharmaceuticals, Inc. (INO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of INO with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a INO analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.